Hot Life Science Investor Mandate 3: European Tech Transfer Office Eyes Several Allocations for 2013 – May 2, 2013

1 May

The technology transfer office of a university based in Europe is currently looking for new investment opportunities in the life science space. They anticipate investing in around eight companies by the end of 2013, and typically allocate between $20,000 and $20 million per firm. Because institutional shareholders back the firm, they have an evergreen structure, and thus can deploy capital as soon as a compelling opportunity is identified.

The tech transfer office is currently most interested in firms in the biotech space, specifically investing in biotech therapeutic and diagnostic firms. They have no particular preference in terms of what indication the company’s product is targeting, and will invest in firms that have products which target orphan indications.

Investing in both pre-revenue companies and companies that have positive cash flow, the tech transfer office will consider firms with products in the preclinical phase of development all the way through firms that have a product on the market. The firm has no strict criteria in terms of revenue and EBITDA for cash flow-positive companies.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: